JournalFrontiers in Cellular and Infection Microbiology
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractCapsular polysaccharide (CPS), which surrounds the bacteria, is one of the most significant and multifaceted contributors to Streptococcus pneumoniae virulence. Capsule prevents entrapment in mucus during colonization, traps water to protect against desiccation, can serve as an energy reserve, and protects the bacterium against complement-mediated opsonization and immune cell phagocytosis. To date, 100 biochemically and serologically distinct capsule types have been identified for S. pneumoniae; 20 to 30 of which have well-defined propensity to cause opportunistic human infection. Among these, serotype 3 is perhaps the most problematic as serotype 3 infections are characterized as having severe clinical manifestations including empyema, bacteremia, cardiotoxicity, and meningitis; consequently, with a fatality rate of 30%–47%. Moreover, serotype 3 resists antibody-mediated clearance despite its inclusion in the current 13-valent conjugate vaccine formulation. This review covers the role of capsule in pneumococcal pathogenesis and the importance of serotype 3 on human disease. We discuss how serotype 3 capsule synthesis and presentation on the bacterial surface is distinct from other serotypes, the biochemical and physiological properties of this capsule type that facilitate its ability to cause disease, and why existing vaccines are unable to confer protection. We conclude with discussion of the clonal properties of serotype 3 and how these have changed since introduction of the 13-valent vaccine in 2000. Copyright Copyright Copyright 2020 Luck, Tettelin and Orihuela.
SponsorsHT and CJO received grant support from NIH grants AI114800 and AI146149.
invasive pneumococcal disease
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14526
- Intranasal Immunization with the Commensal <i>Streptococcus mitis</i> Confers Protective Immunity against Pneumococcal Lung Infection.
- Authors: Shekhar S, Khan R, Schenck K, Petersen FC
- Issue date: 2019 Mar 15
- A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large <i>cps</i> Fragment from an Oral Streptococcus.
- Authors: Ganaie F, Saad JS, McGee L, van Tonder AJ, Bentley SD, Lo SW, Gladstone RA, Turner P, Keenan JD, Breiman RF, Nahm MH
- Issue date: 2020 May 19
- Capsule Promotes Intracellular Survival and Vascular Endothelial Cell Translocation during Invasive Pneumococcal Disease.
- Authors: Brissac T, Martínez E, Kruckow KL, Riegler AN, Ganaie F, Im H, Bakshi S, Arroyo-Diaz NM, Spencer BL, Saad JS, Nahm MH, Orihuela CJ
- Issue date: 2021 Oct 26
- Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection.
- Authors: Nagai K, Domon H, Maekawa T, Hiyoshi T, Tamura H, Yonezawa D, Habuka R, Saitoh A, Terao Y
- Issue date: 2019 Jan 3
- The Pneumococcal Serotype 15C Capsule Is Partially O-Acetylated and Allows for Limited Evasion of 23-Valent Pneumococcal Polysaccharide Vaccine-Elicited Anti-Serotype 15B Antibodies.
- Authors: Spencer BL, Shenoy AT, Orihuela CJ, Nahm MH
- Issue date: 2017 Aug